events
O’Melveny’s Life Sciences CLE Day 2016
September 29, 2016 | Life Sciences
O’Melveny’s Life Sciences partners are hosting a Life Sciences CLE Day, complete with panel discussions on hot topics facing life sciences companies and networking opportunities with in-house counsel from pharmaceutical companies on September 29, 2016, in our New York office.
The day’s agenda includes the following topics, as well as a networking breakfast with Judge Faith Hochberg and a panel with O’Melveny partner Ross Galin; Doug Lankler, Executive Vice President and General Counsel of Pfizer; Matt Maletta, Executive Vice President and Chief Legal Officer of Endo Pharmaceuticals; and Allen Waxman, Executive Vice President of Market Access at Eisai Inc.:
- The Supreme Court and Life Sciences: Jon Hacker and Anton Metlitsky
- Cybersecurity: The Board’s Role: Danielle Gray and Jeremy Maltby
- Enforcement Trends and Risk Mitigation Strategies Related to Pharma Distribution Channels: Steve Brody, David Kirman, and Caitlin Bair
- Mass Tort Defense Strategies: Rich Goetz, Amy Laurendeau, and Houman Ehsan
- The New Face of Pharma Patent Litigation: Biosimilars, Brand v. Brand and 505(b)(2): Lisa Pensabene and Dan O’Boyle
- Choosing the Right Medicine: How to Identify and Mitigate Risk in Life Science M&A: Toby Knapp and Rob Ennis
- Emerging Trends in State AG Litigation: Charlie Lifland and Carolyn Kubota
- FDA Perspectives on Use of Social Media in Product Promotion: Seth Ray
- The Role of the Constitution and Administrative Procedure Act in Post-Grant Patent Proceedings: Filko Prugo and Margaret O’Boyle
- “Product Hopping,” Life Cycle Management, and the Namenda Decision: Ted Hassi and Steve McIntyre
